Belle Mead, NJ, United States of America

Hao Zhang

USPTO Granted Patents = 35 

 

Average Co-Inventor Count = 5.6

ph-index = 8

Forward Citations = 275(Granted Patents)


Location History:

  • Golden, CO (US) (2022)
  • Flushing, NY (US) (2022)
  • Belle Mead, NJ (US) (2002 - 2023)

Company Filing History:


Years Active: 2002-2025

where 'Filed Patents' based on already Granted Patents

35 patents (USPTO):

Title: Hao Zhang: A Prolific Inventor in LPA Receptor Inhibitors

Introduction:

In the realm of pharmaceutical innovations, Hao Zhang, based in Belle Mead, NJ, is a renowned inventor with a remarkable portfolio of patents. With a focus on the development of compounds known as LPA (Lysophosphatidic acid) receptor inhibitors, Zhang has made significant contributions to the field.

Latest Patents:

Zhang's latest patents demonstrate his expertise in LPA receptor inhibitors. One of his recent inventions is the "Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists." This patent introduces a novel class of compounds (Formula I), selective LPA receptor inhibitors, which hold promising potential for various therapeutic applications.

Additionally, Zhang's patent for "Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists" extends his innovative work in this area. This invention, represented by compounds of Formula I, further emphasizes the development of selective LPA receptor inhibitors for potential use in pharmaceutical applications.

Career Highlights:

Over the course of his career, Zhang has accumulated an impressive total of 30 patents. His dedication to research and development has firmly established him as a notable figure in the field of pharmaceutical innovations. Zhang's patents highlight his continuous pursuit of novel LPA receptor inhibitors and his ability to bring groundbreaking concepts to life.

Collaborations:

Throughout his professional journey, Zhang has collaborated with esteemed colleagues, Yan Shi and Peter Tai Wah Cheng, on various projects. These collaborations have further enriched his research endeavors and established a collaborative network within the field. By working alongside individuals who share his passion for innovation, Zhang has fostered an environment conducive to driving scientific advancements.

Conclusion:

Hao Zhang's expertise in the development of selective LPA receptor inhibitors has propelled him to the forefront of pharmaceutical innovations. With an impressive patent portfolio and collaborations with esteemed researchers, Zhang continues to push the boundaries of scientific discovery. As the global healthcare industry evolves, the contributions of inventors like Hao Zhang become vital, offering new possibilities and advancements in the treatment of various diseases and conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…